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Abstract
Background. Hydrochlorothiazide (HCT) is applied in
the therapy of familial hypomagnesaemia with hyper-
calciuria and nephrocalcinosis (FHHNC) caused by
claudin-16 (CLDN16) mutation. However, the short-
term efﬁcacy of HCT to reduce hypercalciuria in
FHHNC has not yet been demonstrated in a clinical
trial.
Methods. Four male and four female patients with
FHHNC and CLDN16 mutation, under long-standing
HCT therapy (0.4–1.2mg/kg, median 0.9mg/kg, dose
according to calciuria), aged 0.7–22.4 years, were
included in a clinical study to investigate the effect of
HCT on calciuria. The study design consisted of three
periods: continued therapy for 4 weeks, HCT with-
drawal for 6 weeks and restart of therapy at the same
dose for 4 weeks. Calciuria and magnesiuria were
assessed weekly as Ca/creat and Mg/creat ratio, every
2 weeks in 24 h urine, and serum Mg, K and kaliuria
(s-Mg, s-K and K/creat) at weeks 0, 6, 10 and 14. The
data of each study period were averaged and analysed
by Friedman and Wilcoxon test.
Results. Ca/creat was signiﬁcantly reduced by
HCT (median before/at/after withdrawal 0.76/1.24/
0.77mol/mol creat; n¼ 8, P<0.05). The reduction
of Ca/24 h by HCT was not statistically signiﬁcant
(0.13/0.19/0.13mmol/kg 24 h; n¼ 5). Serum Mg
(0.51/0.64/0.56mmol/l; n¼ 8, P<0.05) and Serum K
(3.65/4.35/3.65mmol/l; n¼ 8, P<0.05) were signiﬁ-
cantly higher during withdrawal. However, Mg/creat
(0.98/0.90/0.90mol/mol creat; n¼ 8), Mg/24 h
(0.14/0.12/0.18mmol/kg 24h; n¼ 5) and K/creat
(6.3/8.4/6.2mol/mol creat; n¼ 8) remained statistically
unchanged during withdrawal.
Conclusions. We demonstrated that HCT is effective
in reducing hypercalciuria due to CLDN16 mutation
on a short-term basis. However, the efﬁcacy of HCT to
attenuate disease progression remains to be elucidated.
Keywords: claudin-16; hydrochlorothiazide;
hypercalciuria
Introduction
Familial hypomagnesaemia with hypercalciuria and
nephrocalcinosis (FHHNC) is a rare autosomal reces-
sive disease caused by mutations in the claudin-16
(CLDN16) gene [1,2]. CLDN16 is located in tight
junctions of the thick ascending limb of Henle,
permitting paracellular passage of Mg and Ca [1–3].
This paracellular pathway is the main location for Mg
re-absorption in the kidney, and is driven by the
positive luminal transepithelial voltage [4]. To date,
28 different mutations in the CLDN16 gene have been
identiﬁed [1–3,5]. The loss of function mutations
result in a selective alteration in paracellular Mg and
Ca permeability [3].
The clinical presentation includes hypomagnesaemia,
hypercalciuria and nephrocalcinosis. The disease prog-
resses at a variable course to chronic and end-stage
renal failure [5–8]. At diagnosis, the symptoms include
urinary tract infections, polyuria–polydipsia, renal
concrements, seizures and ocular and hearing impair-
ment. Further biochemical abnormalities are hyper-
uricaemia, elevated levels for parathyroid hormone and
hypocitraturia [5–10].
For treatment, hydrochlorothiazide (HCT) is applied
in order to reduce hypercalciuria [5,6,11–13]. HCT is
reported to effectively reduce hypercalciuria of various
aetiologies [14,15]. However, the efﬁcacy of HCT in
FHHNC caused by CLDN16 mutation has not yet
been demonstrated in a clinical trial. Since the nature
of FHHNC is quite distinct from idiopathic hyper-
calciuria, data may not be transferred from one
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disease to another. Furthermore, it is not known to
what degree HCT therapy can attenuate disease pro-
gression towards end-stage renal failure [5,6,8,10,11].
Concerning adverse effects, thiazide diuretics are
well known to induce hypokalaemia. Additionally,
although little is known about the effects of thiazide
diuretics on renal magnesium excretion, chronic admin-
istration of thiazides may result in renal Mg wasting
[4,14,16,17]. Hypomagnesaemia has been reported to
be unresponsive to Mg administration in patients with
CLDN16 mutation [5,10,11,13].
The aim of our clinical study was to investigate
the short-term efﬁcacy of HCT on hypercalciuria in
patients with CLDN16 mutation, and to explore the
signiﬁcance of therapy-induced short-term adverse
effects, such as hypomagnesaemia and hypokalaemia.
Methods
Study design
All clinical experimentation was conducted in accordance
with the guidelines proposed in the Declaration of Helsinki.
The local ethics committee approved this monocentre open
trial. Written informed consent of the patients and/or their
legal representatives was obtained. The central hypothesis
was that HCT is effective in reducing hypercalciuria in
patients with CLDN16 mutation. All patients had been under
HCT treatment for at least 3 months before the study entry.
Drug doses had been individually chosen and titrated to
calciuria (HCT dose at study start and end, and concomitant
medication are listed in Table 1). The study design consisted
of three periods: continuation of HCT therapy at prior
dose for 4 weeks (‘before withdrawal’), a wash-out phase
of 2 weeks and further HCT withdrawal for 4 weeks
(‘at withdrawal’), and restart of HCT therapy at the dose
ultimately used for 4 weeks (‘after withdrawal’). During
therapy periods, the titration of HCT dose to calciuria was
performed if necessary (Table 1). During the study period,
urinary calcium/creatinine ratio and magnesium/creatinine
ratio (Ca/creat and Mg/creat) were assessed weekly. Calcium
and magnesium excretion in 24 h (Ca/24 h and Mg/24 h) was
measured every 2 weeks. At weeks 0, 6, 10 and 14, serum
magnesium, serum potassium and potassium/creatinine ratio,
(s-Mg, s-K and K/creat) were examined. Further biochemical
data of the patients, as serum creatinine, glomerular ﬁltration
rate (estimated following the Schwartz formula) and serum
calcium are listed in Table 1.
Patients
Four male and four female patients from ﬁve families,
aged 0.7–22.4 years (median 12.0 years), with FHHNC
caused by CLDN16 mutation, were enrolled. Inclusion
criteria for the study were CLDN16 mutation in at least one
allele, hypomagnesaemia, hypercalciuria, nephrocalcinosis,
and optionally chronic renal failure. Clinical diagnosis
of FHHNC and CLDN16 gene analysis were obtained
between early infancy and age 18.5 years. Gene analysis
was performed by Konrad and coworkers [5]. Out of eight
patients, two were homozygous for Leu151Phe, two patients
were compound heterozygous for Leu145Pro/Leu151Phe and
four patients were heterozygous for Leu151Phe (Table 1).
Figure 1 shows the pedigrees of the ﬁve families that the
patients belong to.
Table 1. Clinical data and biochemical values of the patients before study start
Patient
no.
sex Age
(years)
s-creat (mg/dl)
at study
start/end
GFR
(ml/min/1.73m2)
at study start/end
s-Ca (mmol/l)
at study
start/end
Results of CLDN16
gene analyse
HCT dose
(mg/kg) at
study start/end
Concomitant medication
(dose per day) at
study start/end
1 M 0.7 0.36/0.45 90/72 2.85/2.59 Heterozygous 0.7/1.4 Mg 1.2mmol/kg
Leu151Phe Fluoride 0.25mg
Ferrum (II) 50mg
2 F 5.3 1.06/1.09 57/56 2.24/2.49 Heterozygous 0.7/1.5 Mg 0.6mmol/kg
Leu151Phe Triamteren 50mg
3 M 8.8 1.07/1.19 64/57 2.53/2.41 Heterozygous 0.9/0.9 Mg 0.5mmol/kg
Leu151Phe Triamteren 50mg
4 M 9.8 0.92/0.85 77/83 2.30/2.45 Heterozygous 0.8/1.0 Mg 0.4mmol/kg
Leu151Phe Triamteren 50mg
Methylphenidan 10mg
5 F 14.3 1.07/1.09 84/82 2.07/2.20 Homozygous 0.8/0.8 Mg 0.3mmol/kg
Leu151Phe Triamteren 100mg
6 M 14.8 1.36/1.53 92/81 2.22/n.d. Homozygous 0.8/0.8 Mg 0.4mmol/kg
Leu151Phe Atenolol 100mg
Colecalciferol 2000 IU
7 F 19.7 1.04/1.27 87/71 2.20/2.37 Compound 1.2/1.2 Mg 0.4mmol/kg
Heterozygous Triamteren 150mg
Leu145Pro/Leu151Phe Losartan 25mg
8 F 22.3 1.07/1.10 87/85 1.93/2.13 Compound 0.4/0.4 Mg 0.5mmol/kg
Heterozygous Triamteren 50mg
Leu145Pro/Leu151Phe Enalapril 5mg
CLDN16, claudin-16; GFR, glomerular ﬁltration rate (calculated according to Schwartz formula); HCT, hydrochlorothiazide; Leu, leucin;
Mg, magnesium; Phe, phenylalanin; s-Ca, serum-calcium; s-creat., serum-creatinine.
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All patients had hypomagnesaemia, hypercalciuria and
bilateral nephrocalcinosis. At the start of the study, patients
had a glomerular ﬁltration rate of 57–92ml/min/1.73m2
(calculated according to Schwartz formula; median
85.5ml/min/1.73m2). The patients had been treated for at
least 3 months (patients 3–8 for more than a year) with HCT
alone (patients 1, 6), or in combination with triamteren
because of hypokalaemia (patients 2–5, 7, 8). The HCT
dose was individually chosen and titrated to calciuria
(0.4–1.2mg/kg body weight, median 0.9mg/kg). In case of
persistent hypercalciuria, the thiazide dose was increased to
125%. All patients received oral Mg according to their s-Mg
levels and individual tolerance (0.3–1.2mmol/kg body weight,
constant dose for each patient throughout the study).
Reference values
Age-speciﬁc reference values were based on literature [18–24]:
 upper normal values for Ca/creatinine ratio: 2.2 (patient 1),
0.8 (patient 2) and 0.7mol/mol creatinine (patients 3–8);
 upper normal values forMg/creatinine ratio: 2.2 (patient 1),
1.0 (patient 2), 0.9 (patients 3 and 4) and 0.6mol/mol
creatinine (patients 5–8);
 potassium/creatinine: female, 1.7–8.7; male,
1.3–8.4mol/mol;
 lower normal value for s-Mg: 0.70mmol/l;
 lower normal value for s-K: 3.70mmol/l and
 upper normal values for calciuria/24 h and magnesiuria/
24 h: 0.1mmol/kg body weight per 24 h.
Statistical analysis
In each of the three periods of the study (before, at and after
withdrawal of HCT), the weekly assessed data of the patients
were averaged, excluding the wash-out phase. Because of the
small sample size, the statistical analysis consisted of non-
parametric tests. The differences between the three phases
were analysed by Friedman test. Post hoc analysis was
performed using Wilcoxon test for paired data. Statistical
signiﬁcance was deﬁned as two-tailed P-value of 0.05.
Data were analysed a second time separately for patients
1–4 (heterozygote for CLDN16 mutation) and patients 5–8
(homozygote or compound heterozygote).
Results
Before withdrawal, HCT was administered at a median dose
of 0.9mg/kg body weight (0.4–1.2mg/kg) and after with-
drawal at a median dose of 1.0mg/kg (0.4–1.5mg/kg). The
differences in HCT dose result from a dose increase in patients
1, 2 and 4 due to persistent hypercalciuria.
Calciuria
Ca/creatinine was signiﬁcantly reduced by HCT-therapy
(median before/at/after withdrawal 0.76/1.24/0.77mol/mol
creatinine; n¼ 8, P<0.05, Figure 2). A separate analysis of
heterozygous patients (patients 1–4) and homozygous/com-
pound heterozygous patients (patients 5–8) showed similar
results (heterozygous patients: median 0.91/1.48/
0.90mol/mol creatinine, n¼ 4, P<0,05; homozygous/com-
pound heterozygous patients: median 0.70/1.13/0.71mol/mol
creatinine, n¼ 4, P<0,05). Patients 1–4 with the higher
Ca/creatinine values were younger than patients 5–8 and
therefore had higher normal values (age 0.7–9.8 vs 14.3–22.3
years). Before HCTwithdrawal, ﬁve out of eight patients were
normocalciuric or slightly hypercalciuric (up to 0.10mol/mol
creatinine above reference value). Three out of eight patients
Patients 1 and 3 Patients 2 and 4
Patient 5 Patient 6
Patients 7 and 8
Fig. 1. Pedigrees of patients 1–8.
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Fig. 2. Urinary calcium/creatinine ratio (mol/mol creatinine) for
patients 1–8, and median value before/at/after HCT withdrawal.
The upper normal value is indicated after each patient number.
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were hypercalciuric, with values 0.15–0.31mol/mol above
age-speciﬁc reference. At HCT withdrawal, seven patients
were hypercalciuric, with values 0.22–1.01mol/mol above
age-speciﬁc reference. After restart of HCT therapy, six patients
returned normocalciuric or slightly hypercalciuric. Two
patients were hypercalciuric with values 0.17–0.27mol/mol
above the age-speciﬁc reference. The two patients with the
highest calcium excretion (patients 1 and 2) were the youngest
patients with a higher normal value compared with the older
patients.
Twenty-four hour urine was only obtained from ﬁve
patients because of age-related limitations. Reduction of
Ca/24 h by HCT was not statistically signiﬁcant, but showed
the same tendency as Ca/creatinine (median 0.13/0.19/
0.13mmol/kg 24 h; n¼ 5). A separate analysis for the
homozygous/compound heterozygous patients showed
nearly identical results (median 0.14/0.19/0.14mmol/kg
24 h; n¼ 4). Because of age, we only had 24 h urine from one
heterozygous patient.
Serum magnesium and urinary magnesium excretion
S-Mg was signiﬁcantly higher during HCT withdrawal
(median before/at/after withdrawal 0.51/0.64/0.56mmol/l;
n¼ 8, P<0.05, Figure 3). Again, separate analysis showed
similar results (heterozygous patients: median 0.56/0.66/
0.59mmol/l, n¼ 4, P<0,05; homozygous/compound hetero-
zygous patients: median 0.45/0.61/0.58mmol/l, n¼ 4,
P<0.05). All patients had hypomagnesaemia during HCT
therapy (values 0.03–0.31mmol/l below reference).
Hypomagnesaemia was less pronounced at HCT withdrawal
(0.06–0.15mmol/l below reference). However, only two
patients achieved normomagnesaemia. In all patients except
patient 6, values for s-Mg decreased after restart of HCT
therapy. None of the patients showed any clinical symptoms
of hypomagnesaemia such as muscle cramps, cardiac
palpitations or seizures throughout the study.
Mg/creatinine remained statistically unchanged during
withdrawal (median 0.98/0.90/0.90mol/mol creatinine;
n¼ 8). The same results could be shown in the separate
analysis (heterozygous patients: median 1.46/1.40/
1.27mol/mol creatinine, n¼ 4; homozygous/compound
heterozygous patients: median 0.85/0.85/0.88mol/mol creati-
nine, n¼ 4). There was no increase of magnesiuria after restart
of HCT therapy. Furthermore, almost all patients showed
hypermagnesiuria throughout the study (except patient 1
before/at/after withdrawal, and patients 3 and 4 after
withdrawal).
Mg/24 h also remained statistically unchanged during
HCT withdrawal. However, there was a tendency towards
increased magnesiuria under HCT therapy (median before/at/
after withdrawal 0.14/0.12/0.18mmol/kg 24 h; n¼ 5).
As we assessed 24 h urine only from one heterozygous
patient, the results of the separate analysis did not relevantly
differ.
Serum potassium and kaliuria
Serum potassium was signiﬁcantly higher during
HCT withdrawal (median before/at/after withdrawal
3.65/4.35/3.65mmol/l; n¼ 8, P<0.05, Figure 4). These
results were reproduced in the separate analysis
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Fig. 3. Serum magnesium (mmol/l) for patients 1–8, and median
value before/at/after HCT withdrawal. The lower normal value is
indicated by the dotted line in the ﬁgure.
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Fig. 4. Serum potassium (mmol/l) for patients 1–8, and median
value before/at/after HCT withdrawal. The lower normal value is
indicated by the dotted line in the ﬁgure.
2130 B. Zimmermann et al.
(heterozygous patients: median 3.60/4.15/3.40mmol/l, n¼ 4,
P<0.05; homozygous/compound heterozygous patients:
median 3.65/4.50/3.65mmol/l, n¼ 4, P<0.05). Half of the
patients were hypokalaemic under HCT therapy at study
start (values 0.2–0.5mmol/l below reference). All patients
achieved normokalaemia at HCT withdrawal. Furthermore,
all patients showed an increase of s-K values at withdrawal.
After restart of HCT therapy, four patients went back into
hypokalaemia (values 0.1–0.8mmol/l below reference). None
of the patients showed any symptoms of hypokalaemia such
as fatigue, constipation or cardiac palpitation throughout
the study.
K/creat remained statistically unchanged during with-
drawal (median 6.3/8.4/6.2mol/mol creatinine; n¼ 8). The
separate analysis showed the same results (heterozygous
patients: median 7.0/9.4/6.7mol/mol creatinine, n¼ 4;
homozygous/compound heterozygous patients: median
5.7/8.4/6.2mmol/l, n¼ 4).
Discussion
We investigated the acute effect of HCT on hyper-
calciuria on eight patients with FHHNC caused by
CLDN16 mutation. The hypocalciuric effect of HCT is,
as recent data suggest, caused by enhanced passive
calcium transport in the proximal tubule [17]. Secondly,
the question of whether clinically signiﬁcant side effects
of HCT therapy could be seen was evaluated.
Our patients were an inhomogeneous group
regarding CLDN16 gene mutation. Patients 5–8 were
homozygous or compound heterozygous for well-
known mutations. In contrast, in patients 1–4 only
one allele of the CLDN16 gene showed a mutation. All
patients showed typical clinical manifestations of the
disease. However, questions remain about genotype/
phenotype correlation in CLDN16 mutation. A recent
publication identiﬁes heterozygous carriers of CLDN16
mutation at risk for hypercalciuria leading to renal
stones or nephrocalcinosis [25]. In patients 1–4
(two pairs of siblings: patients 1/3 and patients 2/4),
only one mutant allele could be detected. This raised
the question of whether these four patients, despite
their typical clinical disease, should be regarded as
heterozygous carriers for CLDN16 mutation rather
than FHHNC patients. As mutation analysis was
performed by direct sequencing of the coding region
and the exon–intron boundaries, it might well be that
the second mutation was missed if it was located
somewhere else in CLDN16. In addition, the phenotype
(marked hypomagnesaemia and chronic renal failure
in at least one sibling of each family) strongly suggests
the diagnosis of FHHNC. Furthermore, haplotype
analysis for CLDN16 region showed the same second
haplotype in both sibling pairs, which is compatible
with linkage analysis to the CLDN16 locus. This
further supports the idea that both patients in the two
families have the same disease.
The separate analysis of our heterozygous and
homozygous/compound heterozygous patients
showed the same results for all parameters as the
analysis of the entire group. As a consequence, the
results for all patients will be discussed together.
We could demonstrate a signiﬁcant reduction of
urinary calcium/creatinine ratio under HCT therapy.
However, the effect was less pronounced in 24 h urine
excretion. The lack of statistical signiﬁcance might
mainly be due to the fact that 24 h urine was only
obtained from ﬁve patients because of age-related
limitations.
The more prominent reduction of calciuria observed
in Patients 1 and 3 could be due to an increased HCT
dose in Patient 1. Furthermore, a habituation effect
to thiazide therapy could play a role, resulting in an
enhanced hypocalciuric effect after restarting therapy.
All patients were hypomagnesaemic under HCT
therapy, and six patients at HCT withdrawal.
However, hypomagnesaemia was less pronounced
during HCT withdrawal. Neither under HCT therapy
nor at withdrawal did our patients show any symptoms
of hypomagnesaemia. Neither muscular cramps,
seizures nor cardiac palpitations during the observation
period were seen, which might indicate a good
adaptation. We could not demonstrate any signiﬁcant
change in magnesiuria under HCT therapy in our
patients. Like serum magnesium, serum potassium
signiﬁcantly dropped during HCT therapy, which did
not result in clinical symptoms such as fatigue or
palpitations. However, we did not see a signiﬁcantly
decreased tubular potassium re-absorption in our
patients under HCT therapy.
Chronic use of thiazide diuretics in patients
with idiopathic hypercalciuria is reported to induce
hypokalaemia (through increased urinary potassium
excretion), as well as renal magnesium wasting
[4,14,16,17]. However, almost all our patients showed
hypermagnesiuria even at HCT withdrawal as a feature
of their CLDN16 mutation. In addition, the high
dose of magnesium supplements might add to the
degree of magnesium excretion. It is conceivable that
patients with CLDN16 mutation only develop a
transient increase of magnesiuria and kaliuria after
start of HCT therapy that might be counter-regulated
by the low serum electrolyte levels, and result in a new
steady state. This seems to be a possible explanation
for statistically unchanged magnesiuria and kaliuria
with or without thiazide treatment. Furthermore,
renal magnesium re-absorption underlies a series of
regulating factors, for example hormonal control,
Mg availability or biochemical changes like metabolic
acidosis or hypokalaemia [4]. Additionally, it cannot
be excluded that thiazide diuretics may have an effect
upon calcium, magnesium or potassium excretion
beyond the kidney. For instance, a decrease in
fecal calcium excretion under HCT therapy has been
reported in patients with idiopathic hypercalciuria [14].
Finally, the exchange of potassium and hydrogen ions
in the tubuli might be altered, which could be examined
by changes in the acid–base status. Taken together,
several factors may account for our observation that
despite the signiﬁcant impact of HCT therapy on serum
magnesium and potassium levels, this effect cannot be
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demonstrated in urinary magnesium and potassium
excretion. Nevertheless, thiazide-induced potassium
and magnesium depletion may enhance the risk of
cardiac events (due to prolonged QT interval).
Additionally, hypokalaemia is known to induce renal
injury via an increase in renin secretion, stimulation
of the sympathetic nervous system, and alteration of
nitric oxide metabolism [26]. For these reasons, regular
cardiac monitoring by electrocardiogram recording
and regular monitoring of serum electrolyte levels is
highly advisable [27,28].
Conclusion
We could demonstrate that HCT is effective in reducing
hypercalciuria in FHHNC due to CLDN16 mutation.
The therapy appears not to be associated with
acute adverse effects of clinical signiﬁcance. Our data
indicate that HCT therapy can be used in patients with
CLDN16 mutation to reduce hypercalciuria. However,
long-term safety and the efﬁcacy of HCT therapy
to attenuate disease progression and prolong renal
survival remains to be analysed.
Acknowledgements. The authors would like to thank Mrs Sibylle
Po¨tz for her excellent assistance throughout the study period and
clinical work.
Conﬂict of interest statement. None declared.
References
1. Simon DB, Lu Y, Choate KA et al. Paracellin-1, a renal tight
junction protein required for paracellular [Mg2þ] resorption.
Science 1999; 285: 103–106
2. Weber S, Hoffmann K, Jeck N et al. Familial hypomagnesaemia
with hypercalciuria and nephrocalcinosis maps to chromosome
3q27 and is associated with mutations in the PCLN-1 gene.
Eur J Hum Genet 2000; 8: 414–422
3. Blanchard A, Jeunemaitre X, Coudol P et al. Paracellin-1 is
critical for magnesium and calcium reabsorption in the human
thick ascending limb of Henle. Kidney Int 2001; 59: 2206–2215
4. Quamme GA. Renal magnesium handling: new insights in
understanding old problems. Kidney Int 1997; 52: 1180–1195
5. Weber S, Schneider L, Peters M et al. Novel Paracellin-1
mutations in 25 families with familial hypomagnesemia with
hypercalciuria and nephrocalcinosis. J Am Soc Nephrol 2001; 12:
1872–1881
6. Wolf MTF, Do¨tsch J, Konrad M, Bo¨swald M, Rascher W.
Follow-up of ﬁve patients with FHHNC due to mutations in the
Paracellin-1 gene. Pediatr Nephrol 2002; 17: 602–608
7. Benigno V, Canonica CS, Bettinelli A, von Vigier RO,
Truttmann AC, Bianchetti MG. Hypomagnesemia hyper-
calciuria nephrocalcinosis: a report of nine cases and a review.
Nephrol Dial Transplant 2000; 15: 605–610
8. Kari JA, Farouq M, Alshaya HO. Familial hypomagnesemia
with hypercalciuria and nephrocalcinosis. Pediatr Nephrol 2003;
18: 506–510
9. Tajima T, Nukae J, Fujieda K. Two heterozygous mutations
of CLDN16 in a Japanese patient with FHHNC. Pediatr
Nephrol 2003; 18: 1280–1282
10. Praga M, Vara J, Gonzalez-Parra E et al. Familial
hypomagnesemia with hypercalciuria and nephrocalcinosis.
Kidney Int 1995; 47: 1419–1425
11. Kuwertz-Broking E, Frund S, Bulla M, Kleta R, August C,
Kisters K. Familial hypomagnesemia-hypercalciuria in 2
siblings. Clin Nephrol 2001; 56: 155–161
12. Monnens L, Starremans P, Bindels R. Great strides in the
understanding of renal magnesium and calcium reabsorption.
Nephrol Dial Transplant 2000; 15: 568–571
13. Mourani C, Khallouf E, Akkari V, Akatcherian C, Cochat P.
Early hypomagnesemia, hypercalciuria and nephrocalcinosis:
two cases in a family. Arch Pediatr 1999; 6: 748–751
14. Yendt ER, Gagne RJA, Cohanim M. The effects of
thiazides in idiopathic hypercalciuria. Am J Med Sci 1966;
251:449–460
15. Sato K, Hasegawa Y, Nakae J et al. Hydrochlorothiazide
effectively reduces urinary calcium excretion in two Japanese
patients with gain-of-function mutations of the calcium-
sensing receptor-gene. J Clin Endocrinol Metabol 2002; 87:
3068–3073
16. Dai LJ, Friedman PA, Quamme GA. Cellular mechanisms
of chlorothiazide and cellular potassium depletion on [Mg2þ]
uptake in mouse distal convoluted tubule cells. Kidney Int 1997;
51: 1008–1017
17. Nijenhuis T, Vallon V, van der Kemp AWCM, Lofﬁng J,
Hoenderop JGJ, Bindels RJM. Enhanced passive Ca2þ
reabsorption and reduced [Mg2þ] channel abundance explains
thiazide-induced hypocalciuria and hypomagnesemia. J Clin
Invest 2005; 115: 1651–1658
18. Matos V, van Melle G, Boulat O, Markert M, Bachmann C,
Guignard J-P. Urinary phosphate/creatinine, calcium/
creatinine, and magnesium/creatinine ratios in a healthy
pediatric population. J Pediatr 1997; 131: 252–257
19. Hicks JM, Bailey J, Bjorn S. Pediatric reference ranges for
plasma magnesium. Clin Chem 1995; 41: 93
20. Greeley C, Snell J, Colaco A. Pediatric reference ranges for
electrolytes and creatinine. Clin Chem 1993; 39: 1172
21. Dirks JH. The kidney and magnesium regulation. Kidney Int
1983; 23: 771–777
22. Geven WB, Monnens LAH, Willems JL. Magnesium metab-
olism in childhood. Miner Electrolyte Metab 1993; 19: 308–313
23. Hoppe B, Michalk D. Harnsteinerkrankungen im Kindesalter.
Monatsschr Kinderheilk 1996; 144: 557–571
24. Fuentes-Arderiu X, Mas-Serra R, de-No-Lengaran C et al.
Multicentre physiological reference values for some urinary
component-to-creatinine (creatininium) concentration ratios.
Clin Chem Lab Med 2005; 43: 958–962
25. Tasic V, Dervisov D, Koceva S, Weber S, Konrad M.
Hypomagnesemia with hypercalciuria and nephrocalcinosis:
case report and a family study. Pediatr Nephrol 2005; 20:
1003–1006
26. Suga S-I, Phillips MI, Ray PE et al. Hypokalemia induces
renal injury and alterations in vasoactive mediators that
favour salt sensitivity. Am J Phyiol Renal Physiol 2001; 281:
F620–F629
27. Foglia PEG, Bettinelli A, Tosetto C et al. Cardiac work up
in primary renal hypokalaemia-hypomagnesaemia (Gitelman
syndrome). Nephrol Dial Transplant 2004; 19: 1398–1402
28. Laragh JH, Sealey JE. Kþ depletion and the progression of
hypertensive disease or heart failure. The pathogenic role of
diuretic-induced aldosterone secretion. Hypertension 2001;
37: 806–810
Received for publication: 21.2.06
Accepted in revised form: 6.3.06
2132 B. Zimmermann et al.
